Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Authors: Odak et al.

Link to paper:

Journal/ Pre-Print: MedRxiv

Tags: Clinical, Immunology/Immunity

Research Highlights

1. Compared to healthy controls (HC), both mild-disease (MD) and severe-disease (SD) COVID19 patients show general lymphopenia and a reduced Treg cell numbers. Lower numbers of NK, NKT, γδ-, and CD8+ T cells in the blood of COVID-19 patients with SD but not in MD

2. Decrease in the proportion of memory/effector CD4 T cells in SD compared to MD patients

3. Convalescing patients (comprised of both MD and SD patients) show decrease in naïve and increase in effector/memory and central memory CD4 and CD8 T cell


The authors assess T cell responses in the blood of COVID-19 patients, which they propose to be used as a potential prognostic biomarker. A general lymphopenia was observed with reduced numbers of Treg cells. They observed low numbers of NK, NKT, γδ-, and CD8+ cells in SD but not MD patients. SD patients showed reduced memory/effector CD4 T cells; MD patients, however, had increased effector/memory CD8 T cell frequencies. Both groups showed increased frequencies of naïve gdT cells. By comparing to a follow-up sample, convalescing patients (comprised of both MD and SD patients) showed a decrease in naïve and increase in effector/memory and central memory CD4 and CD8 T cells.

Impact for SARS-CoV2/COVID19 research efforts

The findings help us to understand the immune response to SARS-CoV2/COVID19, and provide further confirmation of reduced T cell numbers in COVID-19.

Study Type

· Clinical Cohort study

Strengths and limitations of the paper


· Authors probe γδ T cells which haven’t been widely studied and follow up some patients to check recovery. They also split T cells into naïve/effector and central memory

· Reasonable number of patients and attempts to match controls

· Use of 11-color flow cytometric panels approved for clinical diagnostics

Standing in the field: d ecrease in lymphocyte cell counts in the blood of COVID-19 patients has been described. The authors have previously published on T cells and viral infection.

Appropriate statistics:

· Two-tailed student t test or Mann-Whitney U test were used to analyse the different groups, not clear which tests were used for which data.

· Did not state whether they check for normal distribution in order to perform a two-tailed student t test.

· No correction for multiple comparisons was performed.

· No statistical analysis performed comparing variables (e.g. co-morbidities) between the healthy, mild and severe groups (but do state no statistical difference in age and gender in SD vs MD patients)

Viral model used: Blood of SARS-CoV-2 positive patients

Translatability: Currently hard to translate; spread of data makes it hard to use the determined parameters to classify patients into severity groups upon admission

Main limitations:

· Study was performed on blood samples and did not include tissue-derived and antigen-specific T cell responses

· Very varied time of sampling after symptom onset and convalescence follow-up (first sampling 2-32 days after symptom onset)

· In the flow cytometry panel: no report of an Fc block as well as live-dead marker in counts panel according to table of Abs and gating strategy. It would have been informative to see plots side-by-side for comparison of healthy vs mild vs severe and/or paired samples for recovery. It appears that the comparison between memory and naïve T cells was performed on non-Tregs only.

· Th subsets are not classified according to chemokine receptors and/or transcription factors and cytokine expression and no functional readouts or activation status of T cells

· It would be useful to compare counts from cytometer to diagnostic counts used in other studies, especially since they claim to be proving biomarker utility

· No follow up samples on healthy controls, so difficult to know natural variability caused by sampling on different days, and differing duration between the 2 samples from one patient

· Non-convalescing group seems to be very skewed by a couple of patients, with many looking the same as convalescing patients